Grannus Therapeutics

Grannus Therapeutics is a pre-clinical stage biotechnology company developing first-in-class Hsp90β-selective inhibitors for the treatment of multiple solid tumors. Unlike prior pan-Hsp90 inhibitors that failed in clinical trials due to dose-limiting toxicities, Grannus's isoform-selective approach targets the beta version of the Hsp90 protein, delivering potent single-agent efficacy and enabling powerful combinations with approved therapies such as PARP inhibitors. The company's science is rooted in research from the University of Notre Dame and Purdue University, and it operates within the IDEA Center Innovation Park.